Metabolomic Technologies Inc. (MTI) is excited to announce the national expansion of its proprietary and innovative test, PolypDx™. This non-invasive, convenient urine test is a…
Edmonton, Alberta, May 27, 2019 - DynaLIFE and Metabolomic Technologies Inc. (MTI) today unveiled a new state-of-the art clinical space in Edmonton enabling the assessment of an innovative…
EDMONTON, Alberta, April 29, 2019 -- Metabolomic Technologies Inc. (MTI), an innovative molecular diagnostics company, announced that the US Patent and Trademark Office has issued…
CADTH (the Canadian Agency for Drugs and Technologies in Health) introduced PolypDx™ in their latest issue on new and emerging health care technologies in Canada. CADTH is a not-for-profit…
MTI is pleased to announce the addition of Dr. Douglas J. Robertson to our Medical Advisory Board for PolypDx™. Dr. Robertson is Professor of Medicine at the Geisel School of Medicine…
MTI's poster entitled “Urine Metabolomic Biomarker Panel for Colorectal Cancer” was recognized as a Presidential Poster at the ACG 2018 Annual Scientific Meeting in Philadelphia.…
It is with great sadness that MTI received the news that Dr. Richard Fedorak passed away today. Dr. Fedorak was the Co-Founder, President and Chief Medical Officer of Metabolomic Technologies…
Global Edmonton's Su-Ling Goh covers the MTI story about the Canadian Assessment of PolypDx™, that will engage expert physicians, clinicians, patients and laboratory specialists…
Metabolomic Technologies Inc. (MTI) today announced the launch of a $1.4 million project that will evaluate a new colorectal cancer screening strategy using PolypDx™, the first…
MTI is excited to be attending the 2018 American College of Gastroenterology Conference in Philadelphia. Team members will be on site ready to discuss PolypDx, the first and only urine…
We are very happy to announce a new Medical Advisory Board for PolypDx™. Members of this Advisory Board will help position PolypDx™ internationally, in their respective medical…
Metabolomic Technologies Inc. has been granted a patent for PolypDx™ by the European Patent Office. PolypDx™ received patent approval in Japan in September, 2015, and in Australia…
MTI's COO, Dr. David Chang, and Senior Scientist, Dr. Lu Deng, presented PolypDx™ at CMEF, as part of the Alberta Medical Devices Mission to China. PolypDx™ was featured as a leading…
MTI is pleased to announce the launch of a new product website for our flagship product, PolypDx™, a non-invasive, urine-based diagnostic test for detection of adenomatous polyps,…
Metabolomic Technologies Inc. is excited to be attending the 2017 China International Medical Equipment Fair, May, 2017 in Shanghai, China. Team members will be on site ready to…
Metabolomic Technologies Inc. is excited to be attending the 2017 Digestive Disease Week Conference, May, 2017 in Chicago, IL. Team members will be on site ready to discuss our non-invasive…
From March 20 to 23, 2017, MTI's Dr. David Chang travelled to Beijing and Tianjin, China, as part of a delegation of medical device companies from Canada. PolypDx™ was featured…
In early February, 2017, Metabolomic Technologies Inc. was granted a patent for its PolypDx™ technology by the Australian Patent Office. PolypDx™ received patent approval in Japan…